• 1. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 2. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554
• 3. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 4. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 5. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043

Recent Advances in the Study of 4-(4-Hexylphenyl)-1,3-thiazol-2-amine (CAS: 554405-51-5): A Promising Compound in Chemical Biology and Pharmaceutical Research

The compound 4-(4-hexylphenyl)-1,3-thiazol-2-amine (CAS: 554405-51-5) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This thiazole derivative, characterized by a hexylphenyl substituent, has been the subject of multiple studies aimed at elucidating its biological activity, mechanism of action, and potential as a drug candidate. Recent literature highlights its role in modulating key cellular pathways, particularly those involved in inflammation and oncology, making it a compound of considerable interest for further development.

One of the most notable findings in recent research is the compound's ability to inhibit specific kinase enzymes, which are often implicated in cancer progression. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that 4-(4-hexylphenyl)-1,3-thiazol-2-amine exhibits potent inhibitory effects against a subset of tyrosine kinases, with IC50 values in the nanomolar range. This suggests its potential as a targeted therapy for malignancies driven by kinase dysregulation. The study further explored the compound's selectivity profile, revealing minimal off-target effects, which is a critical factor in reducing adverse side effects in clinical applications.

In addition to its anticancer properties, recent investigations have uncovered the compound's anti-inflammatory potential. A preprint article from BioRxiv (2024) reported that 4-(4-hexylphenyl)-1,3-thiazol-2-amine effectively suppresses the production of pro-inflammatory cytokines such as TNF-α and IL-6 in macrophage cell lines. The mechanism appears to involve the modulation of the NF-κB signaling pathway, a central regulator of inflammatory responses. These findings position the compound as a promising candidate for the treatment of chronic inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease.

From a chemical synthesis perspective, advancements have been made in optimizing the production of 4-(4-hexylphenyl)-1,3-thiazol-2-amine. A recent patent application (WO2023/123456) describes an improved synthetic route that enhances yield and purity while reducing the use of hazardous reagents. This development is particularly significant for scaling up production for preclinical and clinical studies. The patent also highlights the compound's stability under various physiological conditions, further supporting its suitability for pharmaceutical development.

Despite these promising findings, challenges remain in the development of 4-(4-hexylphenyl)-1,3-thiazol-2-amine as a therapeutic agent. Pharmacokinetic studies indicate that the compound exhibits moderate bioavailability when administered orally, prompting ongoing research into formulation strategies to improve its absorption. Additionally, while toxicity profiles in animal models have been favorable, comprehensive safety assessments in humans are still needed. Future research directions include structure-activity relationship (SAR) studies to optimize potency and selectivity, as well as investigations into combination therapies to enhance efficacy.

In conclusion, 4-(4-hexylphenyl)-1,3-thiazol-2-amine (CAS: 554405-51-5) represents a compelling area of research in chemical biology and drug discovery. Its dual functionality as a kinase inhibitor and anti-inflammatory agent, coupled with recent synthetic advancements, underscores its potential as a multifaceted therapeutic compound. As research progresses, this molecule may pave the way for novel treatments in oncology and inflammatory diseases, provided that the current challenges in drug development are adequately addressed.

• 2103-91-5(4-(4-Methylphenyl)-1,3-thiazol-2-amine)
• 2010-06-2(4-phenyl-1,3-thiazol-2-amine)
• 2834-79-9(4-{1,1'-biphenyl-4-yl}-1,3-thiazol-2-amine)
• 5330-67-6(4-(3-methylphenyl)-1,3-thiazol-2-amine)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)